Global footprint Grifols operates across 30 countries with a large workforce and a focus on plasma-derived medicines, indicating opportunities to cross-sell complementary diagnostics, transfusion, and manufacturing solutions to multiple regional teams and affiliates.

Growth and profitability Recent revenue and EBITDA figures show a growing top line with solid margins, suggesting capacity for expanded procurement of enterprise-scale operational tools, cloud platforms, and automation to sustain efficiency across supply and manufacturing operations.

Digital backbone Utilization of technologies such as Apache Kafka, Tableau, Azure, SAP Concur, and automation tools points to readiness for advanced analytics, data integration, and workflow automation opportunities to optimize plasma collection, production, and quality control.

Expansion projects Plans to open new facilities in Ontario and other regions, plus modular automated systems, indicate demand for scalable infrastructure, secure data handling, and logistics support to accelerate site onboarding and regulatory-compliant operations.

Rare disease focus Recent product launches for rare bleeding disorders and specialized immunohematology solutions signal potential needs in specialized laboratory equipment, companion software, and loss-prevention analytics to support niche therapeutic areas.